Impact of CES1 Genotype on Remimazolam

RecruitingOBSERVATIONAL
Enrollment

120

Participants

Timeline

Start Date

September 6, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
AdultMiddle AgedElective Surgical Procedures
Interventions
DRUG

Remimazolam besylate

"This is an observational study, meaning that no interventions are actually administered to the participants. However, blood and urine samples will be collected for research purposes.~Participants will receive remimazolam besylate for at least 2 hours during anesthesia and surgery. Blood will be drawn to determine the concentration of remimazolam in the blood at the following time points: (1) before remimazolam administration, (2) after remimazolam administration has lasted at least 2 hours without a change in concentration, (3) immediately before discontinuation of remimazolam if there has been a change in concentration since the second blood draw, (4) within 5 minutes of discontinuation, (5) within 15-60 minutes of discontinuation, and (6) 90 minutes after discontinuation. Urine will also be collected after the end of anesthesia to check for metabolites of remimazolam."

Trial Locations (1)

08308

RECRUITING

Korea University Guro Hospital, Seoul

All Listed Sponsors
lead

Korea University Guro Hospital

OTHER